Emerging Markets Earnings Roundup: Roche (Part 7)
This article was originally published in PharmAsia News
Executive Summary
Roche’s international growth in pharmaceuticals was a modest 2% in the second quarter, a likely reason for a generally subdued earnings call. But the tone was upbeat on the second half with a few clues offered on M&A strategy.